Avastin (bevacizumab) [product information]. EMA.

Regulatory approval published by the European Medicines Agency.

Citation

Mabxience Research SL. Avastin (bevacizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Revised March 2023. Accessed March 11, 2024.

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
Bevacizumab, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.	2

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type	Biomarker(s)	Cancer type	Therapy(ies)
Sensitivity (+)	EGFR p.L858R	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib
Sensitivity (+)	EGFR Exon 19 (Deletion)	Non-Small Cell Lung Cancer	Bevacizumab, Erlotinib